CO2019008364A2 - Composiciones farmacéuticas que comprenden meloxicam - Google Patents

Composiciones farmacéuticas que comprenden meloxicam

Info

Publication number
CO2019008364A2
CO2019008364A2 CONC2019/0008364A CO2019008364A CO2019008364A2 CO 2019008364 A2 CO2019008364 A2 CO 2019008364A2 CO 2019008364 A CO2019008364 A CO 2019008364A CO 2019008364 A2 CO2019008364 A2 CO 2019008364A2
Authority
CO
Colombia
Prior art keywords
meloxicam
pharmaceutical compositions
drug
compositions
rizatriptane
Prior art date
Application number
CONC2019/0008364A
Other languages
English (en)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of CO2019008364A2 publication Critical patent/CO2019008364A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

RESUMEN En la presente se dan a conocer composiciones que comprenden un fármaco, tal como un triptano (por ejemplo, rizatriptano) y/o un NSAID (por ejemplo, meloxicam) en combinación con una ciclodextrina y/o un carbonato o un bicarbonato. Estas composiciones se pueden administrar por la vía oral, por ejemplo, con el fin de mejorar la biodisponibilidad o la farmacocinética del fármaco para el tratamiento de las afecciones tales como el dolor.
CONC2019/0008364A 2017-01-04 2019-07-30 Composiciones farmacéuticas que comprenden meloxicam CO2019008364A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762442136P 2017-01-04 2017-01-04
US201762504105P 2017-05-10 2017-05-10
US201762536466P 2017-07-25 2017-07-25
PCT/US2018/012433 WO2018129220A1 (en) 2017-01-04 2018-01-04 Pharmaceutical compositions comprising meloxicam

Publications (1)

Publication Number Publication Date
CO2019008364A2 true CO2019008364A2 (es) 2019-08-20

Family

ID=62791365

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0008364A CO2019008364A2 (es) 2017-01-04 2019-07-30 Composiciones farmacéuticas que comprenden meloxicam

Country Status (20)

Country Link
US (4) US10137131B2 (es)
EP (2) EP3789016A1 (es)
JP (3) JP6870867B2 (es)
KR (4) KR102493541B1 (es)
CN (1) CN110621314A (es)
AU (3) AU2018205790B2 (es)
CA (2) CA3049229C (es)
CO (1) CO2019008364A2 (es)
CY (1) CY1123820T1 (es)
DK (1) DK3565550T3 (es)
ES (1) ES2845566T3 (es)
HR (1) HRP20210034T1 (es)
HU (1) HUE052749T2 (es)
LT (1) LT3565550T (es)
MX (2) MX2019008127A (es)
PL (1) PL3565550T3 (es)
PT (1) PT3565550T (es)
RS (1) RS61346B1 (es)
SI (1) SI3565550T1 (es)
WO (1) WO2018129220A1 (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10532101B1 (en) 2015-02-10 2020-01-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758618B2 (en) 2015-02-10 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780166B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10799588B2 (en) 2015-02-10 2020-10-13 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11045549B2 (en) 2015-02-10 2021-06-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11110173B2 (en) 2015-02-10 2021-09-07 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US10729774B1 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10512692B2 (en) 2015-02-10 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821181B2 (en) 2015-02-10 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11738085B2 (en) 2015-02-10 2023-08-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013805B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10653777B2 (en) 2015-02-10 2020-05-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10058614B2 (en) 2015-02-10 2018-08-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10702602B2 (en) 2015-02-10 2020-07-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11607456B2 (en) 2015-02-10 2023-03-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933136B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10537642B1 (en) 2015-02-10 2020-01-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729773B2 (en) 2015-02-10 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695429B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10695430B2 (en) 2015-02-10 2020-06-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11013806B2 (en) 2015-02-10 2021-05-25 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10933137B2 (en) 2015-02-10 2021-03-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10517950B1 (en) 2015-02-10 2019-12-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11602563B2 (en) 2015-02-10 2023-03-14 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10780165B2 (en) 2015-02-10 2020-09-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10722583B2 (en) 2015-02-10 2020-07-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433078B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10561664B1 (en) * 2017-01-04 2020-02-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583088B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11801250B2 (en) 2017-01-04 2023-10-31 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10905693B2 (en) 2017-01-04 2021-02-02 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11266657B2 (en) 2017-01-04 2022-03-08 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10583144B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10821182B2 (en) 2017-06-29 2020-11-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729697B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
CN110621314A (zh) 2017-01-04 2019-12-27 艾克萨姆治疗公司 包含美洛昔康的药物组合物
US10471014B2 (en) 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617755B2 (en) 2017-01-04 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11433079B2 (en) 2017-01-04 2022-09-06 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10729696B2 (en) 2017-01-04 2020-08-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11471465B2 (en) 2017-01-04 2022-10-18 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10894053B2 (en) 2017-01-04 2021-01-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10940153B2 (en) 2017-01-04 2021-03-09 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11207327B2 (en) 2017-01-04 2021-12-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11806354B2 (en) 2017-01-04 2023-11-07 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
CN117017997A (zh) * 2017-05-10 2023-11-10 艾克萨姆治疗公司 包含美洛昔康的药物组合物
US10512693B2 (en) 2017-06-29 2019-12-24 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11617791B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11865117B2 (en) 2017-06-29 2024-01-09 Axsome Therapeutics, Inc Pharmaceutical compositions comprising meloxicam
US10987358B2 (en) 2017-06-29 2021-04-27 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11712441B2 (en) 2017-06-29 2023-08-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10758617B2 (en) 2017-06-29 2020-09-01 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11759522B2 (en) 2017-06-29 2023-09-19 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688185B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11219626B2 (en) 2017-06-29 2022-01-11 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11510927B2 (en) 2017-06-29 2022-11-29 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10918722B2 (en) 2017-06-29 2021-02-16 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10688102B2 (en) 2017-06-29 2020-06-23 Axsome Therapeutics, Inc. Combination treatment for migraine and other pain
US11617756B2 (en) 2017-06-29 2023-04-04 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US11185550B2 (en) 2017-06-29 2021-11-30 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
WO2020069138A1 (en) * 2018-09-28 2020-04-02 Axsome Therapeutics, Inc. Dosage forms comprising active pharmaceutical ingredients
CN109111469A (zh) * 2018-10-09 2019-01-01 中国药科大学 一种含氯诺昔康的共无定形复合物
EP3920909A4 (en) 2019-02-06 2022-11-30 Axsome Therapeutics, Inc. PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM
US20240058354A1 (en) * 2020-04-06 2024-02-22 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
KR20220164557A (ko) * 2020-04-06 2022-12-13 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 제약 조성물
WO2022122122A1 (en) 2020-12-08 2022-06-16 Symrise Ag Medicament for fighting inflammatory conditions of human skin (i)
US20230355637A1 (en) * 2020-12-31 2023-11-09 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
KR20230125826A (ko) * 2020-12-31 2023-08-29 액섬 테라퓨틱스, 인크. 멜록시캄을 포함하는 약학 조성물

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284269A (en) 1993-06-28 1994-02-08 Petrie Jack G Space saving double seal
WO1996005199A1 (de) 1994-08-12 1996-02-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Imidazopyridinsalz
AU688087B2 (en) 1994-08-13 1998-03-05 Yuhan Corporation Novel pyrimidine derivatives and processes for the preparation thereof
US5872145A (en) 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6586458B1 (en) 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US6077539A (en) 1996-11-12 2000-06-20 Pozen, Inc. Treatment of migraine headache
KR100231723B1 (ko) 1996-12-28 1999-11-15 김영환 플래쉬 메모리 장치
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
NZ502990A (en) 1997-08-27 2002-02-01 Hexal Ag Pharmaceutical compositions of meloxicam with improved solubility and bioavailability
ES2234324T3 (es) * 1998-11-02 2005-06-16 MERCK & CO., INC. Combinaciones de un agonista 5ht1b/1d y un inhibidor selectivo de cox-2 para el tratamiento de la migraña.
SE9804314D0 (sv) 1998-12-14 1998-12-14 Astra Ab New pharmaceutical formulation
MXPA01009658A (es) 1999-03-26 2003-06-24 Pozen Inc Composiciones de dihidroergotamina de alta potencia.
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
MXPA03011017A (es) 2001-06-01 2005-04-29 Pozen Inc Composiciones farmaceuticas para la entrega coordinada de nsaids.
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
JP4616009B2 (ja) 2002-12-26 2011-01-19 ポーゼン インコーポレイテッド ＮＳＡＩＤｓおよびトリプタンを含有する多層剤型
US8512727B2 (en) 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20040214861A1 (en) * 2003-03-28 2004-10-28 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitors and 5-HT1B1D antagonists for the treatment and prevention of migraine
EP1718303A4 (en) 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
US9016221B2 (en) 2004-02-17 2015-04-28 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
CA2565941A1 (en) 2004-05-04 2005-11-10 Equitech Corporation Improved nsaid composition
JP4617774B2 (ja) * 2004-08-26 2011-01-26 コニカミノルタホールディングス株式会社 カラートナー及びカラーフィルター
US20060105045A1 (en) 2004-11-08 2006-05-18 Buchanan Charles M Cyclodextrin solubilizers for liquid and semi-solid formulations
US9265732B2 (en) 2006-03-06 2016-02-23 Pozen Inc. Dosage forms for administering combinations of drugs
US20070281927A1 (en) 2006-06-06 2007-12-06 Shanthakumar Tyavanagimatt Anti-inflammatory and analgesic compositions and related methods
WO2008006216A1 (en) 2006-07-14 2008-01-17 Mistral Pharma, Inc. Anti-inflammatory and cytoprotectant chronotherapy
US20080103189A1 (en) * 2006-10-19 2008-05-01 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted indoles
US20090068262A1 (en) * 2007-04-04 2009-03-12 Ilan Zalit Rapid dissolution of combination products
EP2244712B1 (en) 2008-01-22 2015-08-05 Thar Pharmaceuticals Inc. In vivo studies of crystalline forms of meloxicam
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
EP2344139A1 (en) 2008-09-09 2011-07-20 AstraZeneca AB Method for delivering a pharmaceutical composition to patient in need thereof
US8236782B2 (en) 2009-05-13 2012-08-07 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
EA201290026A1 (ru) 2009-06-25 2012-07-30 Астразенека Аб Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
CN101987081B (zh) 2010-07-16 2012-08-08 钟术光 一种控释制剂
DE102010052847A1 (de) 2010-11-29 2012-05-31 Temmler Werke Gmbh Verfahren zur Herstellung einer PPI-haltigen pharmazeutischen Zubereitung
CN102526058A (zh) 2010-12-28 2012-07-04 秦引林 一种含氯诺昔康和埃索美拉唑消炎镇痛药物组合物
BR112014016085A8 (pt) 2011-12-28 2017-07-04 Pozen Inc composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
WO2014161131A1 (en) 2013-04-01 2014-10-09 Arissa Pharma PREPARING AMORPHOUS MELOXICAM-β-CYCLODEXTRIN INCLUSION COMPLEX VIA SPRAY DRYING PROCESS
US20170216305A1 (en) 2014-09-29 2017-08-03 Arissa Pharma Ltd. Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain
US10058614B2 (en) 2015-02-10 2018-08-28 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US9821075B2 (en) * 2015-02-10 2017-11-21 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
NZ742220A (en) * 2015-02-10 2023-07-28 Axsome Therapeutics Inc Pharmaceutical compositions comprising meloxicam
US10583088B2 (en) 2017-01-04 2020-03-10 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
US10471014B2 (en) 2017-01-04 2019-11-12 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising meloxicam
CN110621314A (zh) 2017-01-04 2019-12-27 艾克萨姆治疗公司 包含美洛昔康的药物组合物
KR102209773B1 (ko) * 2017-05-29 2021-01-28 주식회사 엘지화학 배터리 모듈

Also Published As

Publication number Publication date
KR102493541B1 (ko) 2023-01-30
AU2020244610A1 (en) 2021-01-21
US10471069B2 (en) 2019-11-12
KR20240013848A (ko) 2024-01-30
JP2021107413A (ja) 2021-07-29
MX2019008127A (es) 2019-12-02
EP3789016A1 (en) 2021-03-10
NZ755129A (en) 2021-10-29
PT3565550T (pt) 2021-01-20
EP3565550B1 (en) 2020-10-28
KR20230017366A (ko) 2023-02-03
US10265324B2 (en) 2019-04-23
JP6870867B2 (ja) 2021-05-12
AU2018205790B2 (en) 2020-07-09
HRP20210034T1 (hr) 2021-04-02
CN110621314A (zh) 2019-12-27
US20180256593A1 (en) 2018-09-13
LT3565550T (lt) 2021-03-25
US20190070192A1 (en) 2019-03-07
US10137131B2 (en) 2018-11-27
CA3049229A1 (en) 2018-07-12
KR20190122659A (ko) 2019-10-30
JP2020503360A (ja) 2020-01-30
KR102627411B1 (ko) 2024-01-18
PL3565550T3 (pl) 2021-07-19
CA3121746A1 (en) 2018-07-12
DK3565550T3 (da) 2021-01-18
HUE052749T2 (hu) 2021-12-28
RS61346B1 (sr) 2021-02-26
SI3565550T1 (sl) 2021-04-30
US10471068B2 (en) 2019-11-12
AU2022200590A1 (en) 2022-03-17
CA3049229C (en) 2021-07-27
AU2020244610B2 (en) 2021-11-04
BR112019013901A2 (pt) 2020-02-04
MX2021014509A (es) 2022-01-06
EP3565550A1 (en) 2019-11-13
CY1123820T1 (el) 2022-05-27
EP3565550A4 (en) 2020-01-22
AU2018205790A1 (en) 2019-07-25
US20180214380A1 (en) 2018-08-02
JP2023144095A (ja) 2023-10-06
KR20210107157A (ko) 2021-08-31
ES2845566T3 (es) 2021-07-27
WO2018129220A1 (en) 2018-07-12
US20190231792A1 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
CO2019008364A2 (es) Composiciones farmacéuticas que comprenden meloxicam
CO2021000789A2 (es) Composiciones farmacéuticas que comprenden meloxicam
MY191574A (en) Pharmaceutical compositions comprising meloxicam
AR104984A1 (es) Compuestos selectivos para pyy y sus usos
ECSP15004752A (es) Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles
CO2019000945A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CO2019000943A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CL2017001026A1 (es) Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención.
UY36202A (es) Composición farmacéutica que comprende hemoglobina recombinante o un agente terapéutico basado en subunidades para el tratamiento de cáncer
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
AR115913A1 (es) Formas de dosificación oral biodisponibles, uso, métodos
DOP2010000327A (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento de nivel de creatinina debido a la administracion de dronedarona
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
ECSP15033649A (es) Un medicamento combinado que comprende fenilefrina y paracetamol
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
CL2016002655A1 (es) Composición farmacéutica para el tratamiento de alopatías relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol
ECSP21006974A (es) Composiciones farmacéuticas que comprenden meloxicam
BR112017014295A2 (pt) composição farmacêutica.
CO2018013792A2 (es) Regímenes de dosificación de vortioxetina para el rápido inicio del efecto antidepresivo
CO2017000354A2 (es) Desmopresina estabilizada
DOP2019000233A (es) Dropropizina en combinacion con ambroxol en la forma farmaceutica de jarabe y tableta
AR099330A1 (es) Uso de paricalcitol en el tratamiento de la anemia inflamatoria
CO2019008347A2 (es) Composición de liberación rápida de cinitaprida y simeticona y proceso para prepararla
MX2020004403A (es) Composiciones farmaceuticas que comprenden safinamida.
CO2020006701A2 (es) Composiciones farmacéuticas orales de lorazepam resistentes al alcohol